CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 138 enrolled
Drug / intervention
Tw1CEother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06314971
NCT06314971N/ACompleted
CompareCT.gov

Predicting Recurrence After Curative-Intent Resection of T1 Colorectal Cancer With Transcriptomics

City of Hope Medical Center·observational·Posted Mar 18, 2024·Updated Jul 3, 2025

In Brief

An observational study evaluating Tw1CE for Colorectal Cancer and 5 related conditions. Completed, enrolled 138 participants across 3 sites in 3 countries.

Detailed Summary

Tumor recurrence significantly affects survival rates following the local resection of submucosal colorectal cancers (T1 CRC). Despite this, there are currently no reliable biomarkers established to predict recurrence in T1 CRC. This study seeks to improve the prediction of recurrence-free survival in individuals who have survived T1 CRC.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Stage I, Colorectal Neoplasms Malignant, Colorectal Cancer Recurrent
CountriesJapan, Spain, United States
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedMar 18, 2024
Enrollment StartMar 15, 2023
Primary CompletionJun 15, 2025
Study CompletionJun 30, 2025
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 2.3 years ago

Interventions

Tw1CEother

A panel of microRNA and messenger RNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor, with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)